P
USRE47223EExpiredUtilityPatentIndex 52

Compositions and methods for the diagnosis and treatment of tumor

Assignee: GENENTECH INCPriority: Jun 20, 2005Filed: Jun 26, 2015Granted: Feb 5, 2019
Est. expiryJun 20, 2025(expired)· nominal 20-yr term from priority
Inventors:DENNIS MARK SPOLAKIS PAULMALLET WILLIAM
C07K 2317/565G01N 33/5756C07K 2317/77C07K 2317/55A61K 2039/505A61P 35/00A23D 7/011C07K 16/3069C07K 2317/92A23D 7/0053C07K 2317/24C11C 1/00A61K 47/6851C12P 7/6409C12N 1/12C12P 7/6463Y02E50/13C12P 7/6427C12N 1/32C12P 7/6472C12P 7/649A61K 47/68033A61K 47/68031Y02E50/10
52
PatentIndex Score
0
Cited by
80
References
36
Claims

Abstract

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A monoclonal antibody produced by the hybridoma cell 3A5.3 that binds to a TAT10772 polypeptide. 
     
     
       2. An isolated antibody that specifically binds a TAT10772 polypeptide, said antibody comprising three light chain hypervariable regions (HVR-L1, HVR-L2and HVR-L3) and three heavy chain hypervariable regions (HVR-H1, HVR-H2 and HVR-H3) wherein:
 (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:119;   (b) HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOS:120-121;   (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:122;   (d) HVR-H1 comprises the amino acid sequence of SEQ ID NO:123;   (e) HVR-H2 comprises the amino acid sequence of any one of SEQ ID NOS:124-127; and   (f) HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS:128-183.   
     
     
       3. An antibody drug conjugate comprising an antibody covalently attached by a linker to one or more toxin drug moieties, the compound having the formula:
   Ab-(L-D)p 
 
       or a pharmaceutically acceptable salt or solvate thereof,
 wherein: 
 Ab is an antibody according to  claim 1  or  2  isolated antibody that specifically binds a TAT10772 polypeptide, said antibody comprising three light chain hypervariable regions (HVR-L1, HVR-L2 and HVR-L3) and three heavy chain hypervariable regions (HVR-H1, HVR-H2 and HVR-H3) 
 wherein: 
 (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:119; 
 (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:121; 
 (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:122; 
 (d) HVR-H1 comprises the amino acid sequence of SEQ ID NO:123; 
 (e) HVR-H2 comprises the amino acid sequence of SEQ ID NO:125; and 
 (f) HVR-H3 comprises the amino acid sequence of SEQ ID NO:183; 
 L is a linker; 
 D is a toxin drug moiety an auristatin; and 
 p is 1 to about 20. 
 
     
     
       4. The antibody drug conjugate of  claim 3  wherein Ab is a humanized 3A5.3 antibody. 
     
     
       5. The antibody drug conjugate of  claim 3  wherein D is a maytansinoid. 
     
     
       6. The antibody drug conjugate of  claim 5  wherein the maytansinoid is DM1. 
     
     
       7. The antibody drug conjugate of  claim 3  wherein D is an auristatin. 
     
     
       8. The antibody drug conjugate of claim  7  3 wherein the auristatin is MMAE or MMAF. 
     
     
       9. The antibody drug conjugate of  claim 3  wherein L is MC-val-cit-PAB or MC. 
     
     
       10. The antibody drug conjugate of  claim 3  wherein L is SMCC, SPP, or BMPEO. 
     
     
       11. The antibody drug conjugate of  claim 3  selected from the formula: Ab-MC-val-cit-PAB-MMAE, Ab-MC-val-cit-PAB-MMAF, Ab-MC-MMAE, and Ab-MC-MMAF, Ab-SPP-DM1, and Ab-SMCC-DM1. 
     
     
       12. The antibody drug conjugate compound of  claim 3  wherein the antibody is attached to the linker through a cysteine thiol of the antibody. 
     
     
       13. A pharmaceutical formulation comprising the antibody drug conjugate of  claim 3 , and a pharmaceutically acceptable diluent, carrier or excipient. 
     
     
       14. The pharmaceutical formulation of  claim 13  further comprising a therapeutically effective amount of a chemotherapeutic agent selected from letrozole, oxaliplatin, doxetaxel, 5-FU, leucovorin, lapatinib, and gemcitabine. 
     
     
       15. An article of manufacture comprising
 an antibody-drug conjugate compound of  claim 3 ; 
 a container; and 
 a package insert or label indicating that the compound can be used to treat cancer characterized by the overexpression of a TAT10772 polypeptide. 
 
     
     
       16. The article of manufacture of  claim 15  wherein the cancer is prostate cancer, cancer of the urinary tract, pancreatic cancer, lung cancer, breast cancer, colon cancer or ovarian cancer. 
     
     
       17. The antibody of  claim 2  which is an antibody fragment. 
     
     
       18. The antibody of  claim 2  which is a chimeric or a humanized antibody. 
     
     
       19. The antibody of  claim 2  which is conjugated to a growth inhibitory agent. 
     
     
       20. The antibody of  claim 2  which is conjugated to a cytotoxic agent. 
     
     
       21. The antibody of  claim 20 , wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes. 
     
     
       22. The antibody of  claim 20 , wherein the cytotoxic agent is a toxin. 
     
     
       23. The antibody of  claim 22 , wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin. 
     
     
       24. The antibody of  claim 22 , wherein the toxin is a maytansinoid. 
     
     
       25. The antibody of  claim 2  which is produced in bacteria. 
     
     
       26. The antibody of  claim 2  which is produced in CHO cells. 
     
     
       27. The antibody of  claim 2  which induces death of a cell to to which it binds. 
     
     
       28. The antibody of  claim 27 , wherein said cell is an ovarian cancer cell. 
     
     
       29. The antibody of  claim 2  which is detectably labeled. 
     
     
       30. The antibody of  claim 2  that comprises the VH is sequence shown as SEQ ID NO:208. 
     
     
       31. An antibody drug conjugate comprising an antibody (Ab) covalently attached by a linker (L) to one or more toxin drug moieties (D), the compound having the formula:
   Ab-(L-D)p   or a pharmaceutically acceptable salt or solvate thereof, wherein:
 Ab is an isolated antibody comprising the VH sequence shown in SEQ ID NO:208 and the VL sequence shown as SEQ ID NO:211; 
 L is a linker; 
 D is an auristatin; and 
 p is 1 to about 20. 
   
     
     
       32. The antibody drug conjugate of claim 31, wherein said conjugate is selected from the group consisting of Ab-MC-val-cit-PAB-MMAE, Ab-MC-val-cit-PAB-MMAF, Ab-MC-MMAE, and Ab-MC-MMAF. 
     
     
       33. The antibody drug conjugate of claim 32 wherein said conjugate is Ab-MC-val-cit-PAB-MMAE. 
     
     
       34. The antibody drug conjugate of claim 3 wherein said conjugate is Ab-MC-val-cit-PAB-MMAE. 
     
     
       35. The antibody drug conjugate of claim 3, wherein said auristatin is MMAE. 
     
     
       36. The antibody drug conjugate of claim 31, wherein said auristatin is MMAE.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.